Clinical trial · no report yet · Phase 3
INTerpath-009
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- NCT06623422 ↗
- Recruiting
- Merck Sharp & Dohme LLC
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Pembrolizumab; Cisplatin; Carboplatin; Pemetrexed; Gemcitabine; Paclitaxel; Intismeran autogene; Placebo
- Arms
- Pembrolizumab + Intismeran autogene · Experimental
- Pembrolizumab + Placebo · Active comparator
- Enrollment
- 680 (estimated)
- Primary outcomes
- Disease-Free Survival (DFS)
- Sponsor
- Merck Sharp & Dohme LLC with ModernaTX, Inc.
- Start
- Oct 21, 2024
- Primary completion
- May 16, 2033 (estimated)
- Results posted
- No
- Registry record
- NCT06623422 · updated Oct 16, 2026